Screener / SEC EDGAR /CIK 0001651308 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

BeOne Medicines Ltd. ONC

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What ONC's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of May 6, 2026, ONC reported $3.38 per share under GAAP and $3.24 on its own adjusted basis: the adjusted number is -4% below GAAP.

GAAP EPS $0.01, release May 7, 2025: $ -145,896 193 % income (loss)* GAAP basic EPS $ 0.01 $ -2.41 100 % per ADS Adjusted basic $ 1.27 $ -1.40 191 % EPS per ADS* GAAP diluted $ 0.01 $ -2.41 100 % EPS per ADS Adjusted dilu Adjusted EPS $1.22, release May 7, 2025: -2.41 100 % per ADS Adjusted basic $ 1.27 $ -1.40 191 % EPS per ADS* GAAP diluted $ 0.01 $ -2.41 100 % EPS per ADS Adjusted diluted EPS $ 1.22 $ -1.40 187 % per ADS* * For an explana +12100% 2025-05 GAAP EPS $3.38, release May 6, 2026: $ 1,270 17,802 % income Adjusted net $ 375,042 $ 136,137 175 % income* GAAP basic $ 2.05 $ 0.01 20,400 % EPS per ADS Adjusted basic EPS per $ 3.38 $ 1.27 166 % ADS* GAAP diluted $ 1.96 $ Adjusted EPS $3.24, release May 6, 2026: % EPS per ADS Adjusted basic EPS per $ 3.38 $ 1.27 166 % ADS* GAAP diluted $ 1.96 $ 0.01 19,500 % EPS per ADS Adjusted diluted EPS $ 3.24 $ 1.22 166 % per ADS* Free Cash $ 160,5 -4% 2026-05
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
ReleaseGAAP EPSAdjusted EPSGap
May 6, 2026 3.38 3.24 -4%
May 7, 2025 0.01 1.22 +12100%
The company's words, latest release
$ 1,270 17,802 % income Adjusted net $ 375,042 $ 136,137 175 % income* GAAP basic $ 2.05 $ 0.01 20,400 % EPS per ADS Adjusted basic EPS per $ 3.38 $ 1.27 166 % ADS* GAAP diluted $ 1.96 $ release
% EPS per ADS Adjusted basic EPS per $ 3.38 $ 1.27 166 % ADS* GAAP diluted $ 1.96 $ 0.01 19,500 % EPS per ADS Adjusted diluted EPS $ 3.24 $ 1.22 166 % per ADS* Free Cash $ 160,5 release

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business

Open on SEC

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

• Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year

• BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior year

• Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarter

• Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion

SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026.

“Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization.”

* For an explanation of our use of non-GAAP financial measures, refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.

totaled $1.9 billion for the third quarter of 2026, representing growth of 33% compared to the prior-year period.

• BRUKINSA: Global sales totaled $1.4 billion for the third quarter of 2026, representing growth of 34% compared to the prior-year period; U.S. sales of BRUKINSA totaled $1.0 billion in the third quarter of 2026, representing growth of 36% compared to the prior-year period.

• TEVIMBRA (tislelizumab): Global sales totaled $243 million in the third quarter of 2026, representing growth of 28% compared to the prior-year period.

• Amgen in-licensed products: Global sales totaled $167 million in the third quarter of 2026, representing growth of 26% compared to the prior-year period.

as a percentage of global product sales for the third quarter of 2026 was 88%, compared to 86% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company’s portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA, which was offset by a non-cash intangible asset impairment charge of $22 million associated with our decision to discontinue promotion of POBEVCY. On an adjusted basis, which does not include depreciation and amortization, or the impairment charge, gross margin as a percentage of product sales increased to 90%, from 86% in the comparable period of the prior year.

The following table summarizes operating expenses for the third quarter of 2026:

The following table summarizes operating expenses for the year-to-date period ended September 30, 2026, and 2025:

increased for the third quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to advancing early clinical programs into late stage and preclinical programs into the clinic.

Selling, General and Administrative (SG&A) Expenses increased for the third quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment to support commercial growth.

GAAP net income for the third quarter of 2026 was $385 million, an increase of $260 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage. Adjusted net income was $539 million, an increase of $235 million over the prior-year period.

For the third quarter of 2026, basic and diluted earnings per share were $0.26 and $0.25 per share and $3.38 and $3.28 per American Depositary Share (ADS), respectively, compared to $0.09 and $0.08 per share and $1.13 and $1.09 per ADS in the prior-year period. On an adjusted basis, basic and diluted earnings per share was $0.36 and $0.35 per share and $4.74 and $4.59 per ADS, respectively, compared to $0.21 and $0.20 per share and $2.76 and $2.65 per ADS in the prior- year period.

for the third quarter of 2026 was $474 million, representing an increase of $119 million over the prior-year period.

For further details on BeOne’s Third Quarter 2026 Financial Statements, please see BeOne’s Quarterly Report on Form 10-Q for the third quarter of 2026 filed with the U.S. Securities and Exchange Commission.

Prior FY 2026 Guidance Current FY 2026 Guidance1 Total revenue $6.6B - $6.8B $6.9B - $7.0B GAAP gross margin % High-80% range High-80% range GAAP operating expenses2 $4.8B - $5.0B $4.9B - $5.0B (combined R&D and SG&A) GAAP operating income2 $1.0B - $1.1B $1.2B - $1.3B Non-GAAP operating $1.7B - $1.8B $1.9B - $2.0B income2,3

2 Does not assume any potential new, material business development activity or unusual/non-recurring items.

3 Non-GAAP operating income is a financial measure that excludes from the corresponding GAAP measure costs related to share-based compensation, depreciation and amortization expense. Guidance assumes that Non-GAAP expenses track overall expense growth.

BeOne’s total revenue guidance for full year 2026 of $6.9 billion to $7.0 billion reflects performance through the third quarter and the Company’s expectations for the remainder of the year. Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and productivity improvements. Guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth.

The Company is providing the following additional guidance on items impacting net income and earnings per ADS:

• Other income (expense): Estimated range of $25 million to $50 million in expense, includes interest amortization from the Royalty Pharma arrangement.

: Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized. The Company continues to evaluate and assess the magnitude but expects the reversal will occur in the fourth quarter of 2026. See Form 10-Q for additional updates.

• Diluted ADS outstanding: The Company expects diluted ADSs outstanding of approximately 118 million.

• Received U.S. Food and Drug Administration (FDA) Priority Review designation for the Phase 3 MANGROVE filing.

• 29 abstracts accepted for presentation at the American Society of Hematology (ASH) 2026 Annual Meeting, including interim analysis results from the Phase 3 MANGROVE study in first-line mantle cell lymphoma (MCL) to be presented during the Plenary Scientific Session.

• Received Japan regulatory approval for the treatment of adult patients with first-line nasopharyngeal cancer.

ZIIHERA (zanidatamab) for which BeOne holds commercialization rights in select markets

• Presented Phase 3 survival data reinforcing benefit of ZIIHERA-containing regimens in first-line HER2+ gastroesophageal adenocarcinoma (GEA) at the European Society for Medical Oncology Congress 2026 (ESMO 2026).

• Received U.S. Food and Drug Administration (FDA) approval for TEVIMBRA-based regimen for first-line HER2+ GEA.

• Tacabrutideg (BTK CDAC): Pivotal Phase 2 portion of CaDAnCe-101 met its primary endpoint of overall response rate in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

• BG-75202 (KAT6 A/B inhibitor): First patient enrolled into monotherapy cohort for the Phase 1 study for the treatment of adult patients with acute myeloid leukemia.

◦ Received Orphan Drug Designation from the European Commission and awarded Innovation Passport, enabling entry to the UK's Innovative Licensing and Access Pathway, in hepatocellular carcinoma (HCC).

• BG-85738 (RAS ONi): First patient enrolled in the Phase 1 study of advanced solid tumors with RAS mutations.

◦ Received FDA Fast Track Designation for the treatment of patients with advanced or metastatic CEA-high non-small cell lung cancer whose disease has progressed following prior systemic therapy.

• BGB 58067 (MTA-cooperative PRMT5 inhibitor): Disclosed first clinical data at ESMO 2026.

• BG-C9074 (B7-H4 ADC): Initiated Starstone-301 Phase 3 study in combination with bevacizumab for the treatment of adult patients with first-line ovarian cancer in maintenance setting.

Programs Milestones Timing •Regulatory submission in Japan BRUKINSA for the treatment of adult Q4 2026 patients with first-line MCL. •China regulatory action for the treatment of adult patients TEVIMBRA with first-line HER2-positive 1H 2027 GEA in combination with ZIIHERA and chemotherapy. •China regulatory action for the treatment of adult patients ZIIHERA with first-line HER2-positive 1H 2027 GEA in combination with chemotherapy, with or without TEVIMBRA. •Phase 2 potential submission Tacabrutideg(BGB-16673) for the treatment of adult Mid 2027 patients with R/R CLL. •CaDAnCe-306: Phase 3 study initiation 1H 2027 for R/R CLL in combination with BEQALZI BGB-B2033 •GroundBBreaker-301 Phase 3 (GPC3x4-1BB bispecific study initiation in second-line Q4 2026 antibody) or later hepatocellular carcinoma. •GroundBBreaker-201 potentially pivotal single-arm Phase 2 study initiation in Q4 2026 second-line or later hepatocellular carcinoma. •GroundBBreaker-302 pivotal Phase 3 study initiation in 1H 2027 first-line hepatocellular carcinoma

• Announced a multi-part collaboration with Revolution Medicines, including a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets.

• Announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening the Company’s U.S manufacturing footprint.

• Announced the renewal of a partnership with the BeOne Care Foundation and The Max Foundation, a leading global health nonprofit organization, to expand access to BRUKINSA for the treatment of adult patients with CLL in low- and middle- income countries through 2028.

The Company’s earnings conference call for the third quarter 2026 will be broadcast via webcast at 8:00 a.m. ET on Thursday, November 5, 2026, and will be accessible through the Investors section of BeOne’s website at www.beonemedicines.com. Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available.

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: BeOne’s continued rapid global growth and leadership in hematology; future catalysts for BeOne’s business; BeOne’s full year 2026 guidance; BeOne’s expectations regarding certain valuation allowances; BeOne’s expectations regarding continued global expansion and investment to support growth; upcoming R&D milestones to be achieved by BeOne; the timing of clinical and regulatory developments and data readouts; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

Investor Contact Media Contact Liza Heapes Meredith Ferguson +1 857-302-5663 +1 216-338-3797 [email protected] [email protected]

(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)

BeOne provides certain non-GAAP financial measures, including Adjusted Cost of Sales- Product, Adjusted Operating Expenses, Adjusted Income from Operations, Adjusted Income Tax Expense, Adjusted Net Income, Adjusted Earnings Per Share, Free Cash Flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne’s operating performance. Adjustments to BeOne’s GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne’s operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne’s management uses for planning and forecasting purposes and measuring BeOne’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

1. Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the relevant tax jurisdiction. Please note that the Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects.

Reconciliation of GAAP Operating Income Guidance to Non-GAAP Operating Income Guidance for Full Year 2026 -Unaudited GAAP operating income 1,200,000 — 1,300,000 Plus: Adjustments to arrive at 700,000 — 700,000 Non-GAAP1 Non-GAAP operating income 1,900,000 — 2,000,000

1. The non-GAAP adjustments are based on actual results through the first nine months of 2026 and best available information at this time related to similar items for the remainder of the year.

Full text with the tables
                
  Exhibit 99.1  
                
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business
Updates

• Total global revenues of $1.9 billion for the third quarter, an increase of
34% from the prior year

• BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,
an increase of 34% from the prior year

• Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the
third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarter

• Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating
income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0
billion

SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX:
06160; SSE: 688235), a global oncology company, today announced financial
results and corporate updates from the third quarter of 2026.

John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:

“Our strong third quarter results and raised full-year guidance reflect
continued rapid global growth and leadership in hematology, anchored by our
foundational BTK inhibitor BRUKINSA, which drives powerful and sustained
responses in patients, and now joined by our next-generation BCL2 inhibitor
BEQALZI. We look forward to multiple catalysts in the coming months from one of
the deepest pipelines in oncology, spanning hematology and solid tumors,
accelerated by our differentiated capabilities in R&D, manufacturing, and
commercialization.”

(Amounts in thousands of U.S. dollars and unaudited)
                                                                                
        Th…                                   Ni…                               
        Mo…                                   Mo…                               
        En…  Se…                %             En…  S…               %           
        20…  30,    20…         Ch…           20…  3…    20…        Ch…         
 ────────────────────────────────────────────────────────────────────────────── 
  N…                                                                            
  p…    $    1,…    $    1,…         33  %    $    5…    $    3…         32  %  
  r…                                                                            
  O…    $    34…    $    17…         1…  %    $    8…    $    3…         1…  %  
  r…                                                                            
  T…    $    1,…    $    1,…         34  %    $    5…    $    3…         33  %  
  r…                                                                            
  G…                                                                            
  i…    $    41…    $    16…         1…  %    $    9…    $    2…         2…  %  
  f…                                                                            
  o…                                                                            
  A…                                                                            
  i…    $    61…    $    34…         79  %    $    1…    $    7…         1…  %  
  f…                                                                            
  o…                                                                            
  G…                                                                            
  n…    $    38…    $    12…         2…  %    $    8…    $    2…         2…  %  
  i…                                                                            
  A…                                                                            
  n…    $    53…    $    30…         77  %    $    1…    $    6…         96  %  
  i…                                                                            
  G…                                                                            
  b…                                                                            
  E…    $    3.…    $    1.…         1…  %    $    7…    $    2…         2…  %  
  p…                                                                            
  A…                                                                            
  A…                                                                            
  b…                                                                            
  E…    $    4.…    $    2.…         72  %    $    1…    $    6…         90  %  
  p…                                                                            
  A…                                                                            
  G…                                                                            
  d…                                                                            
  E…    $    3.…    $    1.…         2…  %    $    7…    $    1…         2…  %  
  p…                                                                            
  A…                                                                            
  A…                                                                            
  d…                                                                            
  E…    $    4.…    $    2.…         73  %    $    1…    $    6…         90  %  
  p…                                                                            
  A…                                                                            
  F…                                                                            
  C…    $    47…    $    35…         34  %    $    1…    $    5…         90  %  
  F…                                                                            
                                                                                
* For an explanation of our use of non-GAAP financial measures, refer to the
“Note Regarding Use of Non-GAAP Financial Measures” section later in this press
release and for a reconciliation of each non-GAAP financial measure to the most
comparable GAAP measures, see the table at the end of this press release.
                
  Exhibit 99.1  
                
                                                                                
  Third Quarter 2026 Financial Results                                          
                                                                                
                                                                                
  Product Revenue                                                               
                                                                                
totaled $1.9 billion for the third quarter of 2026, representing growth of 33%
compared to the prior-year period.

• BRUKINSA: Global sales totaled $1.4 billion for the third quarter of 2026,
representing growth of 34% compared to the prior-year period; U.S. sales of
BRUKINSA totaled $1.0 billion in the third quarter of 2026, representing growth
of 36% compared to the prior-year period.

• TEVIMBRA (tislelizumab): Global sales totaled $243 million in the third
quarter of 2026, representing growth of 28% compared to the prior-year period.

• Amgen in-licensed products: Global sales totaled $167 million in the third
quarter of 2026, representing growth of 26% compared to the prior-year period.
                                                                                
  Gross Margin                                                                  
                                                                                
as a percentage of global product sales for the third quarter of 2026 was 88%,
compared to 86% in the prior-year period on a GAAP basis. The gross margin
percentage increased due to a proportionally higher sales mix of global BRUKINSA
compared to other products in the Company’s portfolio. Gross margin also
benefited from productivity improvements resulting in lower costs for both
BRUKINSA and TEVIMBRA, which was offset by a non-cash intangible asset
impairment charge of $22 million associated with our decision to discontinue
promotion of POBEVCY. On an adjusted basis, which does not include depreciation
and amortization, or the impairment charge, gross margin as a percentage of
product sales increased to 90%, from 86% in the comparable period of the prior
year.
                                                                                
  Operating Expenses                                                            
                                                                                
The following table summarizes operating expenses for the third quarter of 2026:
                                                                                
      (u…                                                                       
      in                                                                        
      th…                                                                       
      ex…        Q3         Q3        %              Q3         Q3        %     
      pe…  GA…  20…       2025      Ch…       Non…  20…       2025      Ch…     
 ────────────────────────────────────────────────────────────────────────────── 
  R…                                                                            
  a…       $    66…    $  523…       26  %    $     58…    $  445…       31  %  
  d…                                                                            
  S…                                                                            
  g…       $    59…    $  528…       12  %    $     50…    $  434…       16  %  
  a…                                                                            
  a…                                                                            
  T…                                                                            
  o…       $    1,…    $  1,0…       19  %    $     1,…    $  880…       24  %  
  e…                                                                            
                                                                                
The following table summarizes operating expenses for the year-to-date period
ended September 30, 2026, and 2025:
                                                                                
      (u…                                                                       
      in                                                                        
      th…        Q3         Q3                       Q3         Q3              
      ex…       YTD        YTD        %             YTD        YTD        %     
      pe…  GA…  20…       2025      Ch…       Non…  20…       2025      Ch…     
 ────────────────────────────────────────────────────────────────────────────── 
  R…                                                                            
  a…       $    1,…    $  1,5…       19  %    $     1,…    $  1,3…       21  %  
  d…                                                                            
  S…                                                                            
  g…       $    1,…    $  1,5…       14  %    $     1,…    $  1,2…       16  %  
  a…                                                                            
  a…                                                                            
  T…                                                                            
  o…       $    3,…    $  3,0…       16  %    $     3,…    $  2,5…       19  %  
  e…                                                                            
                                                                                
                                                                                
  Research and Development (R&D) Expenses                                       
                                                                                
increased for the third quarter of 2026 compared to the prior-year period on
both a GAAP and adjusted basis due to advancing early clinical programs into
late stage and preclinical programs into the clinic.

Selling, General and Administrative (SG&A) Expenses increased for the third
quarter of 2026 compared to the prior-year period on both a GAAP and adjusted
basis due to continued investment to support commercial growth.
                                                                                
  Net Income and Basic/Diluted Earnings Per Share                               
                                                                                
GAAP net income for the third quarter of 2026 was $385 million, an increase of
$260 million over the prior-year period, primarily attributable to revenue
growth and improved operating leverage. Adjusted net income was $539 million, an
increase of $235 million over the prior-year period.
                
  Exhibit 99.1  
                
For the third quarter of 2026, basic and diluted earnings per share were $0.26
and $0.25 per share and $3.38 and $3.28 per American Depositary Share (ADS),
respectively, compared to $0.09 and $0.08 per share and $1.13 and $1.09 per ADS
in the prior-year period. On an adjusted basis, basic and diluted earnings per
share was $0.36 and $0.35 per share and $4.74 and $4.59 per ADS, respectively,
compared to $0.21 and $0.20 per share and $2.76 and $2.65 per ADS in the prior-
year period.
                                                                                
  Free Cash Flow                                                                
                                                                                
for the third quarter of 2026 was $474 million, representing an increase of $119
million over the prior-year period.

For further details on BeOne’s Third Quarter 2026 Financial Statements, please
see BeOne’s Quarterly Report on Form 10-Q for the third quarter of 2026 filed
with the U.S. Securities and Exchange Commission.
                                                                                
  Full Year 2026 Guidance                                                       
                                                                                
BeOne’s financial guidance is summarized below:
                                                                                
                            Prior FY 2026 Guidance    Current FY 2026           
                                                      Guidance1                 
  Total revenue             $6.6B - $6.8B             $6.9B - $7.0B             
  GAAP gross margin %       High-80% range            High-80% range            
  GAAP operating                                                                
  expenses2                 $4.8B - $5.0B             $4.9B - $5.0B             
  (combined R&D and                                                             
  SG&A)                                                                         
  GAAP operating income2    $1.0B - $1.1B             $1.2B - $1.3B             
  Non-GAAP operating        $1.7B - $1.8B             $1.9B - $2.0B             
  income2,3                                                                     
                                                                                
1 Assumes November 1, 2026 foreign exchange rates.

2 Does not assume any potential new, material business development activity or
unusual/non-recurring items.

3 Non-GAAP operating income is a financial measure that excludes from the
corresponding GAAP measure costs related to share-based compensation,
depreciation and amortization expense. Guidance assumes that Non-GAAP expenses
track overall expense growth.

BeOne’s total revenue guidance for full year 2026 of $6.9 billion to $7.0
billion reflects performance through the third quarter and the Company’s
expectations for the remainder of the year. Gross margin percentage is expected
to be in the high-80% range and includes the impact of product mix and
productivity improvements. Guidance for combined operating expenses on a GAAP
basis includes expectations of investment to support growth.

The Company is providing the following additional guidance on items impacting
net income and earnings per ADS:

• Other income (expense): Estimated range of $25 million to $50 million in
expense, includes interest amortization from the Royalty Pharma arrangement.

•
                                                                                
  Income tax outlook                                                            
                                                                                
: Earnings may provide sufficient positive evidence to reverse certain valuation
allowances in 2026, resulting in a material tax benefit when recognized. The
Company continues to evaluate and assess the magnitude but expects the reversal
will occur in the fourth quarter of 2026. See Form 10-Q for additional updates.

• Diluted ADS outstanding: The Company expects diluted ADSs outstanding of
approximately 118 million.
                                                                                
  Third Quarter 2026 Business Highlights                                        
                                                                                
                                                                                
  Core Marketed Products                                                        
                                                                                
BRUKINSA (zanubrutinib)

• Received U.S. Food and Drug Administration (FDA) Priority Review designation
for the Phase 3 MANGROVE filing.

• Completed Phase 3 MANGROVE regulatory submissions in the EU and China.

• 29 abstracts accepted for presentation at the American Society of Hematology
(ASH) 2026 Annual Meeting, including interim analysis results from the Phase 3
MANGROVE study in first-line mantle cell lymphoma (MCL) to be presented during
the Plenary Scientific Session.

BEQALZI (sonrotoclax)

• 10 abstracts accepted for presentation at ASH 2026.

TEVIMBRA (tislelizumab)

• Received Japan regulatory approval for the treatment of adult patients with
first-line nasopharyngeal cancer.
                
  Exhibit 99.1  
                
ZIIHERA (zanidatamab) for which BeOne holds commercialization rights in select
markets

• Presented Phase 3 survival data reinforcing benefit of ZIIHERA-containing
regimens in first-line HER2+ gastroesophageal adenocarcinoma (GEA) at the
European Society for Medical Oncology Congress 2026 (ESMO 2026).

• Received U.S. Food and Drug Administration (FDA) approval for TEVIMBRA-based
regimen for first-line HER2+ GEA.
                                                                                
  Select Clinical-Stage Programs                                                
                                                                                
Hematology

• 6 Tacabrutideg abstracts accepted for presentation at ASH 2026.

• Tacabrutideg (BTK CDAC): Pivotal Phase 2 portion of CaDAnCe-101 met its
primary endpoint of overall response rate in patients with relapsed/refractory
chronic lymphocytic leukemia (CLL).

• BG-75202 (KAT6 A/B inhibitor): First patient enrolled into monotherapy cohort
for the Phase 1 study for the treatment of adult patients with acute myeloid
leukemia.

Gastrointestinal Cancers

• BGB-B2033 (GPC3x4-1BB bispecific antibody):

◦ Updated data presented at ESMO 2026.

◦ Received Orphan Drug Designation from the European Commission and awarded
Innovation Passport, enabling entry to the UK's Innovative Licensing and Access
Pathway, in hepatocellular carcinoma (HCC).

• BG-85738 (RAS ONi): First patient enrolled in the Phase 1 study of advanced
solid tumors with RAS mutations.

Lung Cancer

• BG-C477 (CEA ADC):

◦ Disclosed first clinical data at ESMO 2026.

◦ Received FDA Fast Track Designation for the treatment of patients with
advanced or metastatic CEA-high non-small cell lung cancer whose disease has
progressed following prior systemic therapy.

• BGB 58067 (MTA-cooperative PRMT5 inhibitor): Disclosed first clinical data at
ESMO 2026.

Breast and Gynecological Cancers

• BG-C9074 (B7-H4 ADC): Initiated Starstone-301 Phase 3 study in combination
with bevacizumab for the treatment of adult patients with first-line ovarian
cancer in maintenance setting.
                                                                                
  Anticipated R&D Milestones                                                    
                                                                                
                                                                                
  Programs                         Milestones                         Timing    
                                   •Regulatory submission in Japan              
  BRUKINSA                         for the treatment of adult         Q4 2026   
                                   patients with first-line MCL.                
                                   •China regulatory action for                 
                                   the treatment of adult patients              
  TEVIMBRA                         with first-line HER2-positive      1H 2027   
                                   GEA in combination with ZIIHERA              
                                   and chemotherapy.                            
                                   •China regulatory action for                 
                                   the treatment of adult patients              
  ZIIHERA                          with first-line HER2-positive      1H 2027   
                                   GEA in combination with                      
                                   chemotherapy, with or without                
                                   TEVIMBRA.                                    
                                   •Phase 2 potential submission                
  Tacabrutideg(BGB-16673)          for the treatment of adult         Mid 2027  
                                   patients with R/R CLL.                       
  •CaDAnCe-306: Phase 3 study                                                   
  initiation                       1H 2027                                      
  for R/R CLL in combination                                                    
  with BEQALZI                                                                  
  BGB-B2033                        •GroundBBreaker-301 Phase 3                  
  (GPC3x4-1BB bispecific           study initiation in second-line    Q4 2026   
  antibody)                        or later hepatocellular                      
                                   carcinoma.                                   
  •GroundBBreaker-201                                                           
  potentially pivotal                                                           
  single-arm Phase 2 study                                                      
  initiation in                    Q4 2026                                      
  second-line or later                                                          
  hepatocellular                                                                
  carcinoma.                                                                    
  •GroundBBreaker-302 pivotal                                                   
  Phase 3                                                                       
  study initiation in              1H 2027                                      
  first-line                                                                    
  hepatocellular carcinoma                                                      
                                                                                
                
  Exhibit 99.1  
                
                                                                                
  Corporate Updates                                                             
                                                                                
• Announced a multi-part collaboration with Revolution Medicines, including a
clinical collaboration to evaluate drug combinations incorporating select
clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four
clinical RAS(ON) inhibitors, and a separate regional rights agreement granting
BeOne exclusive development and commercialization rights to these Revolution
Medicines assets in select Asian markets.

• Announced a voluntary agreement with the U.S. Government to expand access to
innovative cancer medicines for American patients while strengthening the
Company’s U.S manufacturing footprint.

• Announced the renewal of a partnership with the BeOne Care Foundation and The
Max Foundation, a leading global health nonprofit organization, to expand access
to BRUKINSA for the treatment of adult patients with CLL in low- and middle-
income countries through 2028.
                                                                                
  BeOne’s Earnings Results Webcast                                              
                                                                                
The Company’s earnings conference call for the third quarter 2026 will be
broadcast via webcast at 8:00 a.m. ET on Thursday, November 5, 2026, and will be
accessible through the Investors section of BeOne’s website at
www.beonemedicines.com. Supplemental information in the form of a slide
presentation, transcript of prepared remarks, and a replay of the webcast will
also be available.
                                                                                
  About BeOne                                                                   
                                                                                
BeOne Medicines is a global oncology company that is discovering and developing
innovative treatments for cancer patients worldwide. With a portfolio spanning
hematology and solid tumors, BeOne is expediting development of its diverse
pipeline of novel therapeutics through its internal capabilities and
collaborations. The Company has a growing global team spanning six continents
who are driven by scientific excellence and exceptional speed to reach more
patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on
LinkedIn, X, Facebook and Instagram.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including statements regarding: BeOne’s continued rapid global growth and
leadership in hematology; future catalysts for BeOne’s business; BeOne’s full
year 2026 guidance; BeOne’s expectations regarding certain valuation allowances;
BeOne’s expectations regarding continued global expansion and investment to
support growth; upcoming R&D milestones to be achieved by BeOne; the timing of
clinical and regulatory developments and data readouts; and BeOne’s plans,
commitments, aspirations and goals under the caption “About BeOne.” Actual
results may differ materially from those indicated in the forward-looking
statements as a result of various important factors, including BeOne’s ability
to demonstrate the efficacy and safety of its drug candidates; the clinical
results for its drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may affect the
initiation, timing and progress of clinical trials and marketing approval;
BeOne’s ability to achieve commercial success for its marketed medicines and
drug candidates, if approved; BeOne’s ability to obtain and maintain protection
of intellectual property for its medicines and technology; BeOne’s reliance on
third parties to conduct drug development, manufacturing, commercialization, and
other services; BeOne’s limited experience in obtaining regulatory approvals and
commercializing pharmaceutical products; BeOne’s ability to obtain additional
funding for operations and to complete the development of its drug candidates
and achieve and maintain profitability; and those risks more fully discussed in
the section entitled “Risk Factors” in BeOne’s most recent periodic report filed
with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions
of potential risks, uncertainties, and other important factors in BeOne’s
subsequent filings with the SEC. All information in this press release is as of
the date of this press release, and BeOne undertakes no duty to update such
information unless required by law. BeOne’s financial guidance is based on
estimates and assumptions that are subject to significant uncertainties.
                                          
  Investor Contact    Media Contact       
  Liza Heapes         Meredith Ferguson   
  +1 857-302-5663     +1 216-338-3797     
  [email protected]     [email protected]  
                                          
                
  Exhibit 99.1  
                
                                                                                
          Condensed Consolidated Statements of Operations (U.S. GAAP)           
                                                                                
 (Amounts in thousands of U.S. dollars, except for shares, American Depositary  
                   Shares (ADSs), per share and per ADS data)                   
                                                                                
           Three                               Nine                             
           Months                              Months                           
           Ended                               Ended                            
           Septem…                             Septe…                           
           30,                                 30,                              
           2026                                2026                             
  Reve…    (Unaud…            2025             (Unau…             2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Prod…                                                                         
  reve…    $        1,855…    $     1,395,…    $       5,022,…    $     3,805…  
  net                                                                           
  Other             34,758           17,271             86,144          39,244  
  reve…                                                                         
  Total             1,889…          1,412,…            5,108,…          3,844…  
  reve…                                                                         
  Cost                                                                          
  of                                                                            
  sales             216,8…          196,510            558,641          526,1…  
  -                                                                             
  prod…                                                                         
  Gross             1,672…          1,215,…            4,549,…          3,318…  
  prof…                                                                         
  Oper…                                                                         
  expe…                                                                         
  Rese…                                                                         
  and               660,7…          523,662            1,814,…          1,530…  
  deve…                                                                         
  Sell…                                                                         
  gene…             593,4…          528,998            1,741,…          1,526…  
  and                                                                           
  admi…                                                                         
  Total                                                                         
  oper…             1,254…          1,052,…            3,556,…          3,056…  
  expe…                                                                         
  Inco…                                                                         
  from              418,6…          163,114            993,624          262,1…  
  oper…                                                                         
  Inte…             33,663           19,393             89,227          43,735  
  inco…                                                                         
  Inte…             -42,4…          -16,364            -115,0…          -31,3…  
  expe…                                                                         
  Other                                                                         
  inco…                429          -18,979             14,216          -6,862  
  (exp…                                                                         
  net                                                                           
  Inco…                                                                         
  befo…             410,3…          147,164            982,034          267,6…  
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  tax               25,654           22,323            132,964          47,182  
  expe…                                                                         
  Net      $        384,7…    $     124,841    $       849,070    $     220,4…  
  inco…                                                                         
  Earn…                                                                         
  per                                                                           
  share                                                                         
  Basic    $          0.26    $        0.09    $          0.58    $       0.16  
  Dilu…    $          0.25    $        0.08    $          0.56    $       0.15  
  Weig…                                                                         
  shar…             1,478…          1,432,…            1,457,…          1,410…  
  outs…                                                                         
  Weig…                                                                         
  shar…             1,524…          1,488,…            1,511,…          1,465…  
  outs…                                                                         
  Earn…                                                                         
  per                                                                           
  Amer…                                                                         
  Depo…                                                                         
  Share                                                                         
  (“AD…                                                                         
  Basic    $          3.38    $        1.13    $          7.58    $       2.03  
  Dilu…    $          3.28    $        1.09    $          7.30    $       1.96  
  Weig…                                                                         
  ADSs              113,6…          110,21…            112,08…          108,4…  
  outs…                                                                         
  Weig…                                                                         
  ADSs              117,3…          114,51…            116,30…          112,7…  
  outs…                                                                         
                                                                                
                
  Exhibit 99.1  
                
          Select Condensed Consolidated Balance Sheet Data (U.S. GAAP)          
                                                                                
                     (Amounts in thousands of U.S. Dollars)                     
                                                                                
                           As of                                                
                           September 30,               December 31,             
                           2026                        2025                     
  Assets:                  (unaudited)                 (audited)                
 ────────────────────────────────────────────────────────────────────────────── 
  Cash, cash                                                                    
  equivalents and          $              5,866,314    $             4,609,647  
  restricted                                                                    
  cash                                                                          
  Accounts receivable,                    1,092,535                    865,080  
  net                                                                           
  Inventories                               807,922                    608,227  
  Property, plant and                     1,647,231                  1,641,678  
  equipment, net                                                                
  Total assets             $              9,875,925    $             8,188,573  
  Liabilities and                                                               
  equity:                                                                       
  Accounts payable         $                496,879    $               479,035  
  Accrued expenses and                    1,342,646                  1,109,120  
  other payables                                                                
  R&D cost share                                  —                     64,345  
  liability                                                                     
  Sale of future                            912,581                    906,956  
  royalty liability                                                             
  Debt                                    1,074,081                  1,019,206  
  Total liabilities                       4,055,531                  3,827,379  
  Total equity             $              5,820,394    $             4,361,194  
                                                                                
                
  Exhibit 99.1  
                
       Select Condensed Consolidated Statements of Cash Flows (U.S. GAAP)       
                                                                                
                     (Amounts in thousands of U.S. Dollars)                     
                                                                                
           Three                               Nine                             
           Months                              Months                           
           Ended                               Ended                            
           Septem…                             Septe…                           
           30,                                 30,                              
           2026                                2026                             
           (unaud…            2025             (unau…             2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Cash,                                                                         
  cash                                                                          
  equi…                                                                         
  and                                                                           
  rest…    $        5,280…    $     2,786,…    $       4,609,…    $     2,638…  
  cash                                                                          
  at                                                                            
  begi…                                                                         
  of                                                                            
  peri…                                                                         
  Net                                                                           
  cash                                                                          
  prov…             508,7…          402,553            1,172,…          710,2…  
  by                                                                            
  oper…                                                                         
  acti…                                                                         
  Net                                                                           
  cash                                                                          
  used              -35,7…          -49,274            -130,6…          -237,…  
  in                                                                            
  inve…                                                                         
  acti…                                                                         
  Net                                                                           
  cash                                                                          
  prov…             102,1…          961,272            164,772          962,5…  
  by                                                                            
  fina…                                                                         
  acti…                                                                         
  Net                                                                           
  effe…                                                                         
  of                                                                            
  fore…             10,499            9,905             49,655          36,862  
  exch…                                                                         
  rate                                                                          
  chan…                                                                         
  Net                                                                           
  incr…                                                                         
  in                                                                            
  cash,                                                                         
  cash              585,6…          1,324,…            1,256,…          1,471…  
  equi…                                                                         
  and                                                                           
  rest…                                                                         
  cash                                                                          
  Cash,                                                                         
  cash                                                                          
  equi…                                                                         
  and                                                                           
  rest…    $        5,866…    $     4,110,…    $       5,866,…    $     4,110…  
  cash                                                                          
  at                                                                            
  end                                                                           
  of                                                                            
  peri…                                                                         
                                                                                
                
  Exhibit 99.1  
                
                                                                                
  Note Regarding Use of Non-GAAP Financial Measures                             
                                                                                
BeOne provides certain non-GAAP financial measures, including Adjusted Cost of
Sales- Product, Adjusted Operating Expenses, Adjusted Income from Operations,
Adjusted Income Tax Expense, Adjusted Net Income, Adjusted Earnings Per Share,
Free Cash Flow and certain other non-GAAP income statement line items, each of
which include adjustments to GAAP figures. These non-GAAP financial measures are
intended to provide additional information on BeOne’s operating performance.
Adjustments to BeOne’s GAAP figures exclude, as applicable, non-cash items such
as share-based compensation, depreciation and amortization. Certain other
special items or substantive events may also be included in the non-GAAP
adjustments periodically when their magnitude is significant within the periods
incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP
current tax expense. The Company currently records a valuation allowance on its
net deferred tax assets, so there is no net impact recorded for deferred tax
effects. BeOne maintains an established non-GAAP policy that guides the
determination of what costs will be excluded in non-GAAP financial measures and
the related protocols, controls and approval with respect to the use of such
measures. BeOne believes that these non-GAAP financial measures, when considered
together with the GAAP figures, can enhance an overall understanding of BeOne’s
operating performance. The non-GAAP financial measures are included with the
intent of providing investors with a more complete understanding of BeOne’s
historical and expected financial results and trends and to facilitate
comparisons between periods and with respect to projected information. In
addition, these non-GAAP financial measures are among the indicators BeOne’s
management uses for planning and forecasting purposes and measuring BeOne’s
performance. These non-GAAP financial measures should be considered in addition
to, and not as a substitute for, or superior to, financial measures calculated
in accordance with GAAP. The non-GAAP financial measures used by BeOne may be
calculated differently from, and therefore may not be comparable to, non-GAAP
financial measures used by other companies.
                
  Exhibit 99.1  
                
                                                                                
         RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES          
                                                                                
 (Amounts in thousands of U.S. Dollars, except for per share and per ADS data)  
                                                                                
                                  (unaudited)                                   
                                                                                
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…    Three                               Nine                             
  cost     Months                              Months                           
  of       Ended                               Ended                            
  sales    Septem…                             Septe…                           
  -        30,                                 30,                              
  prod…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  cost                                                                          
  of       $        216,8…    $     196,510    $       558,641    $     526,1…  
  sales                                                                         
  -                                                                             
  prod…                                                                         
  Less:              5,596            4,261             15,442          10,195  
  Depr…                                                                         
  Less:                                                                         
  Amor…             23,598            1,537             26,932           8,459  
  of                                                                            
  inta…                                                                         
  Less:                  —                —                  —             893  
  Other                                                                         
  Adju…                                                                         
  cost                                                                          
  of       $        187,7…    $     190,712    $       516,267    $     506,5…  
  sales                                                                         
  -                                                                             
  prod…                                                                         
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…                                                                         
  rese…                                                                         
  and                                                                           
  deve…                                                                         
  GAAP                                                                          
  rese…    $        660,7…    $     523,662    $       1,814,…    $     1,530…  
  and                                                                           
  deve…                                                                         
  Less:                                                                         
  Shar…             56,474           58,839            168,866          164,9…  
  comp…                                                                         
  cost                                                                          
  Less:             18,142           18,919             59,400          54,291  
  Depr…                                                                         
  Adju…                                                                         
  rese…    $        586,1…    $     445,904    $       1,586,…    $     1,311…  
  and                                                                           
  deve…                                                                         
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…                                                                         
  sell…                                                                         
  gene…                                                                         
  and                                                                           
  admi…                                                                         
                                                                                
  GAAP                                                                          
  sell…                                                                         
  gene…    $        593,4…    $     528,998    $       1,741,…    $     1,526…  
  and                                                                           
  admi…                                                                         
  Less:                                                                         
  Shar…             76,143           81,947            224,566          221,7…  
  comp…                                                                         
  cost                                                                          
  Less:             13,582           12,550             40,769          32,712  
  Depr…                                                                         
  Less:                                                                         
  Amor…                 16               17                 50              45  
  of                                                                            
  inta…                                                                         
  Adju…                                                                         
  sell…                                                                         
  gene…    $        503,7…    $     434,484    $       1,476,…    $     1,271…  
  and                                                                           
  admi…                                                                         
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…                                                                         
  oper…                                                                         
  expe…                                                                         
  GAAP                                                                          
  oper…    $        1,254…    $     1,052,…    $       3,556,…    $     3,056…  
  expe…                                                                         
  Less:                                                                         
  Shar…             132,6…          140,786            393,432          386,7…  
  comp…                                                                         
  cost                                                                          
  Less:             31,724           31,469            100,169          87,003  
  Depr…                                                                         
  Less:                                                                         
  Amor…                 16               17                 50              45  
  of                                                                            
  inta…                                                                         
  Adju…                                                                         
  oper…    $        1,089…    $     880,388    $       3,062,…    $     2,582…  
  expe…                                                                         
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…                                                                         
  inco…                                                                         
  from                                                                          
  oper…                                                                         
  GAAP                                                                          
  inco…    $        418,6…    $     163,114    $       993,624    $     262,1…  
  from                                                                          
  oper…                                                                         
  Plus:                                                                         
  Shar…             132,6…          140,786            393,432          386,7…  
  comp…                                                                         
  cost                                                                          
  Plus:             37,320           35,730            115,611          97,198  
  Depr…                                                                         
  Plus:                                                                         
  Amor…             23,614            1,554             26,982           8,504  
  of                                                                            
  inta…                                                                         
  Plus:                  —                —                  —             893  
  Other                                                                         
  Adju…                                                                         
  inco…    $        612,2…    $     341,184    $       1,529,…    $     755,4…  
  from                                                                          
  oper…                                                                         
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…                                                                         
  inco…                                                                         
  tax                                                                           
  expe…                                                                         
  GAAP                                                                          
  inco…    $        25,654    $      22,323    $       132,964    $     47,182  
  tax                                                                           
  expe…                                                                         
  Plus:                                                                         
  Disc…             11,527              926            -41,847           9,663  
  tax                                                                           
  items                                                                         
  Plus:                                                                         
  Inco…                                                                         
  tax                                                                           
  effe…             27,995           17,044             68,668          45,747  
  of                                                                            
  non-…                                                                         
  adju…                                                                         
  Adju…                                                                         
  inco…    $        65,176    $      40,293    $       159,785    $     102,5…  
  tax                                                                           
  expe…                                                                         
                                                                                
                
  Exhibit 99.1  
                
                                                                                
  Reco…                                                                         
  of       Three                               Nine                             
  GAAP     Months                              Months                           
  to       Ended                               Ended                            
  adju…    Septem…                             Septe…                           
  net      30,                                 30,                              
  inco…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  net      $        384,7…    $     124,841    $       849,070    $     220,4…  
  inco…                                                                         
  Plus:                                                                         
  Shar…             132,6…          140,786            393,432          386,7…  
  comp…                                                                         
  expe…                                                                         
  Plus:             37,320           35,730            115,611          97,198  
  Depr…                                                                         
  Plus:                                                                         
  Amor…             23,614            1,554             26,982           8,504  
  of                                                                            
  inta…                                                                         
  Plus:                  —                —                  —             893  
  Other                                                                         
  Plus:                                                                         
  Impa…                                                                         
  of                     —           18,722                  —          34,216  
  equi…                                                                         
  inve…                                                                         
  Plus:                                                                         
  Disc…             -11,5…             -926             41,847          -9,663  
  tax                                                                           
  items                                                                         
  Plus:                                                                         
  Inco…                                                                         
  tax                                                                           
  effe…             -27,9…          -17,044            -68,668          -45,7…  
  of                                                                            
  non-…                                                                         
  adju…                                                                         
  Adju…                                                                         
  net      $        538,7…    $     303,663    $       1,358,…    $     692,6…  
  inco…                                                                         
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…                                                                         
  EPS -                                                                         
  basic                                                                         
  GAAP                                                                          
  earn…                                                                         
  per      $          0.26    $        0.09    $          0.58    $       0.16  
  share                                                                         
  -                                                                             
  basic                                                                         
  Plus:                                                                         
  Shar…               0.09             0.10               0.27            0.27  
  comp…                                                                         
  expe…                                                                         
  Plus:               0.03             0.02               0.08            0.07  
  Depr…                                                                         
  Plus:                                                                         
  Amor…               0.02             0.00               0.02            0.01  
  of                                                                            
  inta…                                                                         
  Plus:               0.00             0.00               0.00            0.00  
  Other                                                                         
  Plus:                                                                         
  Impa…                                                                         
  of                  0.00             0.01               0.00            0.02  
  equi…                                                                         
  inve…                                                                         
  Plus:                                                                         
  Disc…              -0.01             0.00               0.03           -0.01  
  tax                                                                           
  items                                                                         
  Plus:                                                                         
  Inco…                                                                         
  tax                                                                           
  effe…              -0.02            -0.01              -0.05           -0.03  
  of                                                                            
  non-…                                                                         
  adju…                                                                         
  Adju…                                                                         
  earn…                                                                         
  per      $          0.36    $        0.21    $          0.93    $       0.49  
  share                                                                         
  -                                                                             
  basic                                                                         
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…                                                                         
  EPS -                                                                         
  dilu…                                                                         
  GAAP                                                                          
  earn…                                                                         
  per      $          0.25    $        0.08    $          0.56    $       0.15  
  share                                                                         
  -                                                                             
  dilu…                                                                         
  Plus:                                                                         
  Shar…               0.09             0.09               0.26            0.26  
  comp…                                                                         
  expe…                                                                         
  Plus:               0.02             0.02               0.08            0.07  
  Depr…                                                                         
  Plus:                                                                         
  Amor…               0.02             0.00               0.02            0.01  
  of                                                                            
  inta…                                                                         
  Plus:               0.00             0.00               0.00            0.00  
  Other                                                                         
  Plus:                                                                         
  Impa…                                                                         
  of                  0.00             0.01               0.00            0.02  
  equi…                                                                         
  inve…                                                                         
  Plus:                                                                         
  Disc…              -0.01             0.00               0.03           -0.01  
  tax                                                                           
  items                                                                         
  Plus:                                                                         
  Inco…                                                                         
  tax                                                                           
  effe…              -0.02            -0.01              -0.05           -0.03  
  of                                                                            
  non-…                                                                         
  adju…                                                                         
  Adju…                                                                         
  earn…                                                                         
  per      $          0.35    $        0.20    $          0.90    $       0.47  
  share                                                                         
  -                                                                             
  dilu…                                                                         
  Reco…                                                                         
  of                                                                            
  GAAP                                                                          
  to                                                                            
  adju…                                                                         
  earn…                                                                         
  per                                                                           
  ADS -                                                                         
  basic                                                                         
  GAAP                                                                          
  earn…                                                                         
  per      $          3.38    $        1.13    $          7.58    $       2.03  
  ADS -                                                                         
  basic                                                                         
  Plus:                                                                         
  Shar…               1.17             1.28               3.51            3.56  
  comp…                                                                         
  expe…                                                                         
  Plus:               0.33             0.32               1.03            0.90  
  Depr…                                                                         
  Plus:                                                                         
  Amor…               0.21             0.01               0.24            0.08  
  of                                                                            
  inta…                                                                         
  Plus:               0.00             0.00               0.00            0.01  
  Other                                                                         
  Plus:                                                                         
  Impa…                                                                         
  of                  0.00             0.17               0.00            0.32  
  equi…                                                                         
  inve…                                                                         
  Plus:                                                                         
  Disc…              -0.10            -0.01               0.37           -0.09  
  tax                                                                           
  items                                                                         
  Plus:                                                                         
  Inco…                                                                         
  tax                                                                           
  effe…              -0.25            -0.15              -0.61           -0.42  
  of                                                                            
  non-…                                                                         
  adju…                                                                         
  Adju…                                                                         
  earn…                                                                         
  per      $          4.74    $        2.76    $         12.12    $       6.38  
  ADS -                                                                         
  basic                                                                         
                                                                                
                
  Exhibit 99.1  
                
                                                                                
  Reconc…                                                                       
  of GAAP                                                                       
  to         Three                              Nine                            
  adjust…    Months                             Months                          
  earnin…    Ended                              Ended                           
  per ADS    September                          Septemb…                        
  -          30,                                30,                             
  diluted    2026                2025           2026               2025         
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  earnin…                                                                       
  per ADS    $           3.28    $      1.09    $          7.30    $      1.96  
  -                                                                             
  diluted                                                                       
  Plus:                                                                         
  Share-…                1.13           1.23               3.38           3.43  
  compen…                                                                       
  expens…                                                                       
  Plus:                  0.32           0.31               0.99           0.86  
  Deprec…                                                                       
  Plus:                                                                         
  Amorti…                0.20           0.01               0.23           0.08  
  of                                                                            
  intang…                                                                       
  Plus:                  0.00           0.00               0.00           0.01  
  Other                                                                         
  Plus:                                                                         
  Impair…                                                                       
  of                     0.00           0.16               0.00           0.30  
  equity                                                                        
  invest…                                                                       
  Plus:                                                                         
  Discre…               -0.10          -0.01               0.36          -0.09  
  tax                                                                           
  items                                                                         
  Plus:                                                                         
  Income                                                                        
  tax                                                                           
  effect                -0.24          -0.15              -0.59          -0.41  
  of                                                                            
  non-GA…                                                                       
  adjust…                                                                       
  Adjust…                                                                       
  earnin…                                                                       
  per ADS    $           4.59    $      2.65    $         11.68    $      6.14  
  -                                                                             
  diluted                                                                       
                                                                                
1. Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the
relevant tax jurisdiction. Please note that the Company currently records a
valuation allowance on its net deferred tax assets, so there is no net impact
recorded for deferred tax effects.
                                                                                
           Three                               Nine                             
           Months                              Months                           
  Free     Ended                               Ended                            
  Cash     Septem…                             Septe…                           
  Flow     30,                                 30,                              
  (Non…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  prov…                                                                         
  by       $        508,7…    $     402,553    $       1,172,…    $     710,2…  
  oper…                                                                         
  acti…                                                                         
  (GAA…                                                                         
  Less:                                                                         
  Purc…                                                                         
  of                                                                            
  prop…             -35,1…          -48,084            -103,4…          -148,…  
  plant                                                                         
  and                                                                           
  equi…                                                                         
  Free                                                                          
  Cash     $        473,5…    $     354,469    $       1,069,…    $     561,9…  
  Flow                                                                          
  (Non…                                                                         
                                                                                
                                                                                
  Reconciliation of GAAP Operating                                              
  Income                                                                        
  Guidance to Non-GAAP                                                          
  Operating Income Guidance for                                                 
  Full Year                                                                     
  2026                                                                          
                                       -Unaudited                               
  GAAP operating income                            1,200,000    —    1,300,000  
  Plus: Adjustments to arrive at                     700,000    —      700,000  
  Non-GAAP1                                                                     
  Non-GAAP operating income                        1,900,000    —    2,000,000  
                                                                                
1. The non-GAAP adjustments are based on actual results through the first nine
months of 2026 and best available information at this time related to similar
items for the remainder of the year.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.